CompletedNot Applicable

Liver Protection of RIPC in Pediatric Living Donor Liver Transplantation

China208 participantsStarted 2016-01

Plain-language summary

Remote ischemic preconditioning(RIPC) is emerging as an promising therapeutic paradigm to combat the detrimental impact of ischemic and reperfusion injury. In liver transplantation, ischemic and reperfusion injury severely impacts the post-surgery liver function and patient outcome. This prospective, double blind, randomized clinical trial is aimed to test the protective effect of RIPC against hepatic ischemic and reperfusion injury in pediatric liver transplantation.

Who can participate

Age range3 Months – 6 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. American society of anesthesiologists score of I-III;
✓. age of 3-72 months
✓. elective living LT surgery.

Exclusion criteria

✕. peripheral vascular disease;
✕. history of thromboembolism;
✕. systemic or local infection before surgery;
✕. autoimmune diseases;
✕. severe congenital heart disease
✕. history of LT.

What they're measuring

Postoperative maximum AST

Timeframe: Postoperative 0-7 day

Postoperative maximum ALT

Timeframe: Postoperative 0-7 day

Trial details

NCT IDNCT02830841

SponsorRenJi Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01

View on ClinicalTrials.gov More Hepatic Ischemic and Reperfusion Injury trials